Table 4.

Association between overall survival time and clinicopathological features of patients with osteosarcoma.

clinicopathological Parameters	studies	Univariate analysis				studies	Multivariate analysis
		pooled HR(95%CI)	P-value	I-squared(%)	Chi-squared(P)		Pooled HR(95%CI)	P-value	I-squared(%)	Chi-squared(P)
Age(≤ 25 vs. > 25)	6	1.01(0.78–1.3)	0.95	0%	0.88
Gender(Female vs. Male)	11	1.15(0.96–1.37)	0.12	0%	0.97
Tumor site (femur,tibia vs. elsewhere)	11	1.15(0.94–1.4)	0.17	18%	0.28
ALP	4	2.13(1.58–2.88)	<0.00001	22%	0.28
Chemotherapy(yes vs. no)	3	1.45(0.46–4.63)	0.53	86%	0.0007
Tumor size(< 8 vs. ≥ 8)	10	1.97(1.55–2.62)	<0.00001	0%	0.64	5	1.28 (0.88–1.86)	0.2	64%	0.02
Metastasis(yes vs. no)	4	2.35 (1.69–3.26)	<0.00001	0%	0.98	7	2.14 (1.15–3.97)	0.02	78%	0.0002
Distant metastasis(presence vs. absence)	7	5.03(3.78–6.69)	<0.00001	0%	0.85	8	4.02 (3.05–5.23)	<0.0001	0%	1
Enneking stage(IIA vs. IIB–III)	6	4.01 (3.08–5.23)	<0.00001	0%	0.64	7	3.2 (2.48–4.14)	<0.0001	0%	0.63
LncRNA expression	11	2.95 (2.37–3.66)	<0.00001	0%	0.93	20	2.16 (1.68–2.79)	<0.00001	54%	0.002